Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

1.

Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.

Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ.

J Immunol. 2013 Oct 15;191(8):4121-9. doi: 10.4049/jimmunol.1203085. Epub 2013 Sep 11.

PMID:
24026081
[PubMed - indexed for MEDLINE]
2.

Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.

Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC.

Mol Immunol. 2012 Jul;51(3-4):263-72. doi: 10.1016/j.molimm.2012.03.023. Epub 2012 Apr 11.

PMID:
22503210
[PubMed - indexed for MEDLINE]
3.

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ Jr.

Cancer Res. 2011 Jul 1;71(13):4617-27. doi: 10.1158/0008-5472.CAN-11-0422. Epub 2011 May 5.

PMID:
21546571
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5. doi: 10.1073/pnas.0813101106. Epub 2009 Feb 11.

PMID:
19211796
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.

Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG.

J Immunother. 2011 Apr;34(3):236-50. doi: 10.1097/CJI.0b013e318209e7ec.

PMID:
21389874
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH.

Mol Ther. 2009 Aug;17(8):1453-64. doi: 10.1038/mt.2009.83. Epub 2009 Apr 21.

PMID:
19384291
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr.

Blood. 2012 Jan 19;119(3):696-706. doi: 10.1182/blood-2011-03-344275. Epub 2011 Nov 23.

PMID:
22117050
[PubMed - indexed for MEDLINE]
Free Article
8.

Enhanced antitumor activity mediated by human 4-1BB-engineered T cells.

Daniel-Meshulam I, Horovitz-Fried M, Cohen CJ.

Int J Cancer. 2013 Dec 15;133(12):2903-13. doi: 10.1002/ijc.28320. Epub 2013 Jul 16.

PMID:
23754772
[PubMed - indexed for MEDLINE]
9.

Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.

Lo AS, Ma Q, Liu DL, Junghans RP.

Clin Cancer Res. 2010 May 15;16(10):2769-80. doi: 10.1158/1078-0432.CCR-10-0043. Epub 2010 May 11.

PMID:
20460472
[PubMed - indexed for MEDLINE]
Free Article
10.

Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.

Hombach AA, Abken H.

Int J Cancer. 2011 Dec 15;129(12):2935-44. doi: 10.1002/ijc.25960. Epub 2011 Mar 29.

PMID:
22030616
[PubMed - indexed for MEDLINE]
11.

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ.

Cancer Res. 2006 Nov 15;66(22):10995-1004.

PMID:
17108138
[PubMed - indexed for MEDLINE]
Free Article
12.

Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells.

Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A, Dotti G, Brenner MK.

Clin Cancer Res. 2009 Sep 15;15(18):5852-60. doi: 10.1158/1078-0432.CCR-08-3163. Epub 2009 Sep 8.

PMID:
19737958
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.

Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE.

Cancer Res. 2003 May 15;63(10):2546-52.

PMID:
12750278
[PubMed - indexed for MEDLINE]
Free Article
14.

Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.

Ma Q, Gomes EM, Lo AS, Junghans RP.

Prostate. 2014 Feb;74(3):286-96. doi: 10.1002/pros.22749.

PMID:
24174378
[PubMed - indexed for MEDLINE]
16.

T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production.

Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL.

J Immunol. 2005 Jun 15;174(12):7853-8.

PMID:
15944290
[PubMed - indexed for MEDLINE]
Free Article
17.

Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.

J Immunol. 2002 Nov 15;169(10):5780-6. Erratum in: J Immunol. 2003 Mar 15;170(6):3440.

PMID:
12421958
[PubMed - indexed for MEDLINE]
Free Article
18.

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.

Blood. 2002 Nov 1;100(9):3155-63. Erratum in: Blood. 2003 May 15;101(10):3808.

PMID:
12384413
[PubMed - indexed for MEDLINE]
Free Article
19.

4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.

Kroon HM, Li Q, Teitz-Tennenbaum S, Whitfield JR, Noone AM, Chang AE.

J Immunother. 2007 May-Jun;30(4):406-16.

PMID:
17457215
[PubMed - indexed for MEDLINE]
20.

A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.

Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE, Cerutti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.

Cancer Gene Ther. 2004 May;11(5):371-9.

PMID:
15060573
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk